Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Philip N. Hawkins(The Royal Free Hospital), James Moon(University of Michigan), Frederick L. Ruberg(Boston University), Claudio Rapezzi(University of Ferrara), John L. Berk(Boston University), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Bouke P. C. Hazenberg(University Medical Center Groningen), Tamer Rezk(Boston University), Andor W.J.M. Glaudemans(Boston University), Sharmila Dorbala(Brigham and Women's Hospital), Frederick W. Vonberg(National Hospital for Neurology and Neurosurgery), Marianna Fontana(Amyloidosis Foundation), Matthew J. Maurer(Mayo Clinic in Arizona), Carol Whelan(The Royal Free Hospital), Sabahat Bokhari(Boston University), Katarina Flatman(Boston University), Ashutosh Wechalekar(University College Hospital), Thibaud Damy(Amyloidosis Foundation), Rodney H. Falk(Brigham and Women's Hospital), Martha Grogan(Mayo Clinic in Arizona), Candida Cristina Quarta(Boston University), Giovanni Palladini(University of Pavia), Paolo Milani(University of Pavia), Geoffrey B. Johnson(Boston University), David F. Hutt(Boston University), Giampaolo Merlini(University of Pavia), Edward J. Miller(Yale University), Pierluigi Guidalotti(Boston University), Angela Dispenzieri(Mayo Clinic), Thirusha Lane(Boston University), Adam Castaño(Columbia University Irving Medical Center)
Cited by 2,005
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k